Generation of anti-insulin-like growth factor-binding protein-related protein 1 (IGFBP-rP1/MAC25) monoclonal antibodies and immunoassay:: Quantification of IGFBP-rP1 in human serum and distribution in human fluids and tissues
被引:24
|
作者:
López-Bermejo, A
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
López-Bermejo, A
Khosravi, J
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
Khosravi, J
Corless, CL
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
Corless, CL
Krishna, RG
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
Krishna, RG
Diamandi, A
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
Diamandi, A
Bodani, U
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
Bodani, U
Kofoed, EM
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
Kofoed, EM
Graham, DL
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
Graham, DL
Hwa, V
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
Hwa, V
Rosenfeld, RG
论文数: 0引用数: 0
h-index: 0
机构:Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
Rosenfeld, RG
机构:
[1] Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97201 USA
[2] Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA
[3] Mt Sinai Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada
The IGF-binding protein (IGFBP)-related proteins (rPs) are a group of recently described cysteine-rich proteins that share significant amino-terminal structural similarity with the conventional IGFBPs. IGFBP-rP1 (also known as MAC25/angiomodulin/prostacyclin-stimulating factor and T1A12), regulates cellular proliferation, adhesion, and angiogenesis and stimulates prostacyclin synthesis. We characterized new monoclonal antibodies generated against IGFBP-rP1 and have used them to study the distribution of IGFBP-rP1 in human biological fluids and tissues. Additionally, we have developed a noncompetitive sandwich-type immunoassay to quantitate the concentrations of IGFBP-rP1 in human serum. IGFBP-rP1 was readily detectable in serum, urine, amniotic fluid, and cerebrospinal fluid by immunoblot analysis. Evaluation of the newly developed immunoassay demonstrated acceptable analytical performance, with a detection limit of 0.7 mug/liter, a dynamic range of 3.1-100 mug/liter, and intra-and interassay coefficients of variation of 2.5-6.8% and 3.1-6.4% at approximately 24-85 ng/ml IGFBP-rP-1, respectively. No significant cross-reactivity with IGFBP-1-6 was observed. In random normal human adult sera (n = 37), the median IGFBP-rP1 was 21.0 mug/liter, and values did not correlate with levels of IGF-I (r = 0.085, P = 0.61), IGF-II (r = 0.051, P = 0.75), or IGFBP-3 (r = 0.061, P = 0.74). The monoclonal anti-IGFBP-rP1 antibodies also readily detected IGFBP-rP1 expression in human tissue sections, with preferential expression of IGFBP-rP1 in the microvascular endothelium associated with tumorigenesis. In summary, using newly developed IGFBP-rP1 monoclonal antibodies, we confirm the presence of IGFBP-rP1 in the major human body fluids, provide quantitative normative data on the concentrations of IGFBP-rP1 in human serum, and show preferential expression of IGFBP-rP1 in the microvascular endothelium associated with tumorigenesis. The use of these novel IGFBP-rP1 detection tools should prove useful in the elucidation of the biological role(s) of this protein.